SCHEMBL10089368

SCHEMBL10089368

CC(C)(C)c1cc(CSc2ccccc2SCc2cc(C(C)(C)C)cc(C(C)(C)C)c2O)c(O)c(C(C)(C)C)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 5/20 0.47
CYP2C9 P11712 4/20 0.47
CYP1A2 P05177 2/20 0.47
CYP3A4 P08684 1/20 0.47
TSHR P16473 1/20 0.47
GAA P10253 2/20 0.41
ALDH1A1 P00352 2/20 0.41
XBP1 P17861 1/20 0.41
MAPK1 P28482 1/20 0.41
HTT P42858 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
HSPA5 P11021 2/20 0.39
HIF1A Q16665 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
ALOX5 P09917 2/20 0.37
PTGS2 P35354 2/20 0.37
CYP2D6 P10635 3/20 0.36
HSP90AA1 P07900 1/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14471348 0.93 CYP2C19 (0.42) CYP2C19CYP2C9CYP1A2CYP3A4TSHR
SCHEMBL10089361 0.85 HIF1A (0.39) CYP2C19CYP2C9CYP1A2CYP3A4TSHR
SCHEMBL10089377 0.81 CYP2D6 (0.37) CYP2C19CYP2C9CYP1A2CYP3A4TSHR
SCHEMBL7241079 0.80 ALDH1A1 (0.47) CYP2C19CYP2C9CYP1A2CYP3A4TSHR
SCHEMBL16320620 0.80 HSPA5 (0.45) CYP2C19CYP2C9CYP1A2CYP3A4TSHR
SCHEMBL6908595 0.79 HSPA5 (0.55) CYP2C19CYP2C9CYP1A2CYP3A4TSHR
SCHEMBL466567 0.78 CYP2C19 (0.50) CYP2C19CYP2C9CYP1A2CYP3A4TSHR
SCHEMBL10089376 0.78 ALDH1A1 (0.45) CYP2C19CYP2C9CYP1A2CYP3A4TSHR
SCHEMBL5873187 0.76 CYP2C19 (0.46) CYP2C19CYP2C9CYP1A2CYP3A4TSHR
SCHEMBL10089385 0.76 CYP2D6 (0.33) CYP2C19CYP2C9CYP1A2CYP3A4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8383753-B2 Polydentate heteroatom ligand containing metal complexes, catalysts and methods of making and using the same DOW GLOBAL TECHNOLOGIES, LLC (US) 2013-02-26 US disclosed
US-8383753-B2 Polydentate heteroatom ligand containing metal complexes, catalysts and methods of making and using the same DOW GLOBAL TECHNOLOGIES, LLC (US) 2013-02-26 US disclosed
US-20120029159-A1 POLYDENTATE HETEROATOM LIGAND CONTAINING METAL COMPLEXES, CATALYSTS AND METHODS OF MAKING AND USING THE SAME DOW GLOBAL TECHNOLOGIES LLC (US) 2012-02-02 US disclosed
US-20120029159-A1 POLYDENTATE HETEROATOM LIGAND CONTAINING METAL COMPLEXES, CATALYSTS AND METHODS OF MAKING AND USING THE SAME DOW GLOBAL TECHNOLOGIES LLC (US) 2012-02-02 US disclosed
US-8071701-B2 Polydentate heteroatom ligand containing metal complexes, catalysts and methods of making and using the same DOW GLOBAL TECHNOLOGIES LLC (US) 2011-12-06 US disclosed
US-8071701-B2 Polydentate heteroatom ligand containing metal complexes, catalysts and methods of making and using the same DOW GLOBAL TECHNOLOGIES LLC (US) 2011-12-06 US disclosed
US-20090221770-A1 POLYDENTATE HETEROATOM LIGAND CONTAINING METAL COMPLEXES, CATALYSTS AND METHODS OF MAKING AND USING THE SAME DOW GLOBAL TECHNOLOGIES INC. 2009-09-03 US disclosed
US-20090221770-A1 POLYDENTATE HETEROATOM LIGAND CONTAINING METAL COMPLEXES, CATALYSTS AND METHODS OF MAKING AND USING THE SAME DOW GLOBAL TECHNOLOGIES INC. 2009-09-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221770-A1 POLYDENTATE HETEROATOM LIGAND CONTAINING METAL COMPLEXES, CATALYSTS AND METHODS OF MAKING AND USING THE SAME PICALM, PARG, POLM CYP2C19 4184/4885CYP2C9 3550/4885CYP1A2 4502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.